December 10, 2020
Data from the APHINITY trial suggested that patients with early breast cancer with a HER2 single-activated pathway determined by molecular subtyping using BluePrint assay demonstrated a trend for greater benefit with adjuvant pertuzumab (Perjeta) therapy.
December 06, 2020
Azacitidine, was shown to significantly prolong overall survival and relapse-free survival in patients with acute myeloid leukemia in first remission regardless of the number of rounds of prior consolidation therapy.